ImmunityBio, Inc. (IBRX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
ImmunityBio, Inc. (IBRX) Bundle
As an investor or analyst, this [Symbol] DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from ImmunityBio, Inc., you can easily adjust forecasts and observe the effects in real-time.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.2 | .6 | .9 | .2 | .6 | .6 | .6 | .7 | .7 | .7 |
Revenue Growth, % | 0 | -72.52 | 54.38 | -74.3 | 159.17 | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 |
EBITDA | -142.3 | -187.9 | -315.4 | -335.5 | -436.2 | -.6 | -.6 | -.7 | -.7 | -.7 |
EBITDA, % | -6461.13 | -31063.47 | -33766.6 | -139796.25 | -70125.72 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 9.0 | 9.1 | 19.1 | 24.2 | 18.5 | .6 | .6 | .7 | .7 | .7 |
Depreciation, % | 409.26 | 1511.9 | 2047.32 | 10080 | 2976.21 | 100 | 100 | 100 | 100 | 100 |
EBIT | -151.3 | -197.1 | -334.5 | -359.7 | -454.7 | -.6 | -.6 | -.7 | -.7 | -.7 |
EBIT, % | -6870.39 | -32575.37 | -35813.92 | -149876.25 | -73101.93 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 51.7 | 96.1 | 317.1 | 107.2 | 266.5 | .6 | .6 | .7 | .7 | .7 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .3 | .0 | 1.3 | 1.9 | 3.2 | .4 | .4 | .4 | .4 | .4 |
Account Receivables, % | 13.76 | 0 | 142.72 | 787.5 | 509.32 | 62.75 | 62.75 | 62.75 | 62.75 | 62.75 |
Inventories | .0 | .0 | .0 | 26.4 | .0 | .1 | .1 | .1 | .1 | .1 |
Inventories, % | 0 | 0 | 0 | 10980.83 | 0 | 20 | 20 | 20 | 20 | 20 |
Accounts Payable | 1.7 | 11.5 | 11.4 | 21.0 | 9.2 | .6 | .6 | .6 | .6 | .7 |
Accounts Payable, % | 79.43 | 1902.48 | 1222.48 | 8756.67 | 1478.3 | 95.89 | 95.89 | 95.89 | 95.89 | 95.89 |
Capital Expenditure | -4.3 | -1.7 | -33.6 | -99.4 | -30.6 | -.6 | -.6 | -.7 | -.7 | -.7 |
Capital Expenditure, % | -194.69 | -275.87 | -3593.47 | -41412.92 | -4917.04 | -100 | -100 | -100 | -100 | -100 |
Tax Rate, % | 0.1192 | 0.1192 | 0.1192 | 0.1192 | 0.1192 | 0.1192 | 0.1192 | 0.1192 | 0.1192 | 0.1192 |
EBITAT | -151.2 | -195.5 | -334.5 | -359.7 | -454.2 | -.6 | -.6 | -.7 | -.7 | -.7 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -145.0 | -177.9 | -350.4 | -452.2 | -453.0 | -6.6 | -.6 | -.7 | -.7 | -.7 |
WACC, % | 9.59 | 9.55 | 9.6 | 9.6 | 9.59 | 9.59 | 9.59 | 9.59 | 9.59 | 9.59 |
PV UFCF | ||||||||||
SUM PV UFCF | -7.9 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -1 | |||||||||
Terminal Value | -9 | |||||||||
Present Terminal Value | -6 | |||||||||
Enterprise Value | -14 | |||||||||
Net Debt | 461 | |||||||||
Equity Value | -475 | |||||||||
Diluted Shares Outstanding, MM | 509 | |||||||||
Equity Value Per Share | -0.93 |
What You Will Get
- Real IBRX Financial Data: Pre-filled with ImmunityBio’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See ImmunityBio’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Clinical Parameters: Adjust key inputs such as patient demographics, treatment efficacy, and trial timelines.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other essential metrics in real-time.
- High-Precision Accuracy: Leverages ImmunityBio's real-world data for credible valuation results.
- Seamless Scenario Analysis: Easily explore various assumptions and evaluate their impacts on outcomes.
- Efficiency Booster: Streamlines the valuation process, removing the need for complex model construction.
How It Works
- Step 1: Download the prebuilt Excel template featuring ImmunityBio's (IBRX) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including ImmunityBio's (IBRX) intrinsic value.
- Step 5: Make well-informed investment choices or create reports based on the outputs.
Why Choose This Calculator for ImmunityBio, Inc. (IBRX)?
- User-Friendly Interface: Tailored for both novice users and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your specific analysis needs.
- Real-Time Feedback: Observe immediate updates to ImmunityBio’s valuation as you modify inputs.
- Pre-Loaded Data: Comes with ImmunityBio’s actual financial figures for swift evaluations.
- Endorsed by Experts: Utilized by investors and analysts for making well-informed decisions.
Who Should Use This Product?
- Healthcare Investors: Make informed decisions with a robust analysis tool tailored for biotech investments.
- Biotech Analysts: Streamline your workflow with a customizable financial model specific to ImmunityBio, Inc. (IBRX).
- Consultants: Effortlessly modify the template for client reports or presentations about ImmunityBio, Inc. (IBRX).
- Biotech Enthusiasts: Expand your knowledge of the biotech sector using real-world examples from ImmunityBio, Inc. (IBRX).
- Educators and Students: Utilize it as a hands-on learning resource in biotechnology and finance courses.
What the Template Contains
- Pre-Filled Data: Includes ImmunityBio’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for computing WACC based on user-defined inputs.
- Key Financial Ratios: Assess ImmunityBio’s profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.